Building upon our previous findings that ENO1 mediates TMZ resistance in GBM, we innovatively evaluated a combinatorial therapeutic strategy targeting the SPHK1 inhibitor PF-543 and TLR4 antagonist TAK-242 alongside TMZ, leveraging its clinical pharmacokinetic profile (Fig. 8A). Here, ENO1 is linked to glioblastoma.